Enveda
Business overview
Enveda is building an AI-powered platform to discover new drugs. The company has shown it can identify new drug candidates 4x faster and at 1/10th the cost of traditional pharma. Today, Enveda has three drug candidates in clinical trials.
Enveda’s drug candidates can be developed and commercialized independently or in partnership with large pharma companies. Partnerships typically involve an upfront payment to Enveda, along with a share of future revenues or profits if the drug is successfully brought to market.
Kinnevik's view
While many successful drugs originally came from nature (like penicillin and morphine), the field slowed down because the process was extremely difficult and inefficient. Enveda is transforming drug discovery by unlocking the vast chemical diversity found in nature through its AI-driven discovery platform. By combining mass spectrometry, machine learning, and advanced robotics, the company can decode complex natural chemistry and identify novel drug candidates from a previously unexplored chemical space.
In just five years, Enveda has built a strong pipeline with multiple development candidates progressing toward clinical milestones in areas such as eczema, asthma, obesity, and metabolic diseases. The three clinical-stage drug candidates together represent more than USD 20bn in potential annual sales, and Enveda’s platform continues to generate additional new candidates.
KPIs
- Leverages mass spectrometry, robotics, and advanced machine-learning techniques to map life’s chemistry and uncover noveltherapeutics - 4x faster and at 1/10 of the cost compared to the industry average
- In five years, Enveda's platform has generated three assets in the clinic, nine assets in IND-enabling studies, and over 20 development candidates
